Drug Approval | March 27, 2024
FDA approves Merck’s WINREVAIR for treatment of pulmonary arterial hypertension
WINREVAIR is a breakthrough biologic for this rare, progressive disease
WINREVAIR is a breakthrough biologic for this rare, progressive disease
Combination shows consistent benefit across prespecified post-progression outcomes
Hepatitis B infects over 40 million people in India
Oscotec has successfully completed phase 2 study in patients with chronic ITP last year
This new medication eliminates the need for cold storage, making it more accessible and affordable for SCD patients across India
Pharma Solutions operates 10 research and development and/or production sites globally
KarXT, Karuna’s lead asset, is a potential first-in-class treatment for Schizophrenia
A five-day inspection was concluded successfully with no critical and no major observations raised
Additional capacity broadens Grace’s fine chemical capabilities for API production
Acquisition to further expand the Alexion, AstraZeneca Rare Disease pipeline beyond complement inhibition
Subscribe To Our Newsletter & Stay Updated
